News

Law

Asset Management

Investment Banking

Wealth

Hedge Funds

People

Newsletters

Events

Lists

Investment Banking

Lazard CEO Jacobs sees ‘pent up’ M&A demand after record 83% profit surge

Ken Jacobs told Financial News that increased confidence following the rollout of the Covid-19 vaccine, as well as expansionary technology-enabled companies was fuelling more dealmaking

Lazard advised on healthcare firm Gilead’s $21bn acquisition of cancer drug-maker Immunomedics
Lazard advised on healthcare firm Gilead’s $21bn acquisition of cancer drug-maker Immunomedics Photo: Getty Images

Lazard chief executive, Ken Jacobs, sees "pent up demand" for M&A fuelling results in 2021 after the independent investment bank ended the year with its a record quarter for its advisory business.

Jacobs told Financial News that increased confidence following the rollout of the Covid-19 vaccine, as well as expansionary technology-enabled companies was fuelling more dealmaking.

WSJ Logo